Equibles does not estimate personal net worth.
Get an email with a short summary when Neurocrine Biosciences Inc publishes a filing, an earnings call transcript or a press release.
Get NBIX alertsSamir Sadanti has spoken on 1 earnings call across 1 company, most recently for Neurocrine Biosciences Inc on July 30, 2026. Neurocrine Biosciences Inc is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Neurocrine Biosciences Inc includes Kevin Gorman (CEO and Board Member), Kyle Gano, Ph.D. (CEO and Board Member), Kyle W. Gano (CEO and Board Member) and 7 others.
“I really appreciate the question on the muskronik. So you know we've got four shots on goal here with our muskronik franchise directly in NBI 568. That's in phase three right now for the treatment of schizophrenia and phase two bipolar, a phase two study right now ongoing in bipolar mania.”
Transcript header (unverified)
Drug Manufacturers - Specialty & Generic · Healthcare
